Headlines about Genocea Biosciences (NASDAQ:GNCA) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genocea Biosciences earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.7897309607799 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s scoring:

GNCA has been the subject of a number of research reports. Robert W. Baird initiated coverage on Genocea Biosciences in a research report on Monday, February 12th. They set an “outperform” rating and a $3.00 target price for the company. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Tuesday, February 6th. Finally, Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $4.21.

Genocea Biosciences (NASDAQ GNCA) remained flat at $$1.01 during midday trading on Monday. 130,355 shares of the company traded hands, compared to its average volume of 1,091,678. Genocea Biosciences has a 12-month low of $0.79 and a 12-month high of $7.29. The stock has a market capitalization of $83.74, a P/E ratio of -0.52 and a beta of 1.31. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of -1.26.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. sell-side analysts predict that Genocea Biosciences will post -0.6 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-genocea-biosciences-gnca-share-price/1909310.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Insider Buying and Selling by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.